Search Results - "Whitworth WC"

Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.

Authors: Ngo HX Xu AY Velásquez GE et al.

Source: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Jun 14; Vol. 78 (6), pp. 1680-1689.

Publication Type: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE

Evaluation of QIAreach QuantiFERON-TB lateral-flow nanoparticle fluorescence assay for TB infection diagnosis among TB household contacts in three high-burden settings.

Authors: Ntshiqa, Thobani Fasanmi, Akinlolu Nagudi, Jeniffer et al.

Source: PLoS ONE. 9/19/2025, Vol. 20 Issue 9, p1-14. 14p.

ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis.

Authors: Harrison, Linda J. Velásquez, Gustavo E. Kempker, Russell R. et al.

Source: Trials. 8/15/2025, Vol. 26 Issue 1, p1-14. 14p.

Evaluating Tuberculosis Screening Tools: A Decade-Long Network Meta-Analysis of Sensitivity and Specificity with Bibliometric Insights.

Authors: Mufida, Diana Chusna Hibatulloh, Muhammad Farhan Fadhil, Muhammad Yusuf et al.

Source: Journal of Global Infectious Diseases. Oct-Dec2025, Vol. 17 Issue 4, p176-186. 11p.

Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.

Authors: Podany AT Pham M Sizemore E et al.

Source: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2022 Sep 10; Vol. 75 (4), pp. 560-566.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.; Research Support, N.I.H., Extramural

Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE

Factors associated with indeterminate QuantiFERON-TB Gold Plus Test results during the COVID-19 pandemic.

Authors: Román-Montes, Carla M. Tamez-Torres, Karla M. Guaracha-Basañez, Guillermo A. et al.

Source: PLoS ONE. 7/21/2025, Vol. 20 Issue 7, p1-11. 11p.

The new gamma interferon (IFN-γ) algorithm for tuberculosis diagnosis in cynomolgus macaques.

Authors: Warit, Saradee Meesawat, Suthirote Cheawchanlertfa, Pattsarun et al.

Source: PLoS ONE. 12/16/2024, Vol. 19 Issue 12, p1-16. 16p.

Evaluation of SARS-CoV-2 interferon gamma release assay in BNT162b2 vaccinated healthcare workers.

Authors: Ramos, Angélica Martins, Sandra Marinho, Ana Sofia et al.

Source: PLoS ONE. 5/10/2024, Vol. 19 Issue 5, p1-13. 13p.

Differences in Clinical Nature and Outcome Among Young Patients Suffering from an Acute Coronary Syndrome.

Authors: Al-Shahrani, Mohammad Saeed Katbi, Faisal Ahmad Al-Sharydah, Abdulaziz Mohammad et al.

Source: Journal of Blood Medicine. Dec2021, Vol. 12, p1011-1017. 7p.

Enhancing the interferon-γ release assay through omission of nil and mitogen values.

Authors: Jung, Yun Jung Park, Ji Eun Park, Ji Won et al.

Source: Respiratory Research. 7/7/2023, Vol. 24 Issue 1, p1-11. 11p.

Advances in clinical trial design: Weaving tomorrow's TB treatments.

Authors: Lienhardt, Christian Nunn, Andrew Chaisson, Richard et al.

Source: PLoS Medicine. 2/27/2020, Vol. 17 Issue 2, p1-12. 12p. 2 Charts.

Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.

Authors: Feng, Zhen Miao, Yan Peng, Ying et al.

Source: BMC Infectious Diseases. 5/8/2023, Vol. 23 Issue 1, p1-11. 11p.

A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB).

Authors: Mlyuka HJ Liyoyo A Nyaulingo B et al.

Corporate Authors: Mlyuka HJ Liyoyo A Nyaulingo B et al.

Source: Trials [Trials] 2026 Jan 30; Vol. 27 (1). Date of Electronic Publication: 2026 Jan 30.

Publication Type: Journal Article; Clinical Trial Protocol

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: MEDLINE

Association of polymorphisms in the TNFA, TNFRSF1A and TNFRSF1B genes with lepromatous leprosy in Western Mexican patients.

Authors: Montoya-Buelna, Margarita Alvarado-Navarro, Anabell Muñoz-Valle, Jose F. et al.

Source: Journal of Infection in Developing Countries. May2024, Vol. 18 Issue 5, p770-778. 9p.

Clinical characteristics of patients with premature acute coronary syndrome and adverse cardiovascular events after PCI.

Authors: Shi, Xiao-Jun Li, Miao-Nan Xuan, Ling et al.

Source: Experimental & Therapeutic Medicine. Jul2019, Vol. 18 Issue 1, p793-801. 9p.

Association of metabolic comorbidity with myocardial infarction in individuals with a family history of cardiovascular disease: a prospective cohort study.

Authors: An, Seokyung Moon, Sungji Park, Sue K.

Source: BMC Public Health. 10/31/2022, Vol. 22 Issue 1, p1-7. 7p. 1 Diagram, 2 Charts, 1 Graph.

Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020.

Authors: Kurbatova EV Whitworth WC Bryant KE et al.

Corporate Authors: Kurbatova EV Whitworth WC Bryant KE et al.

Source: Emerging infectious diseases [Emerg Infect Dis] 2025 Dec; Vol. 31 (12), pp. 2233-2242.

Publication Type: Journal Article; Clinical Trial, Phase III

Journal Info: Publisher: National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC) Country of Publication: United States NLM ID: 9508155 Publication Model: Print Cited Medium: Internet ISSN: 1080-6059 (Electronic) Linking ISSN: 10806040 NLM ISO Abbreviation: Emerg Infect Dis Subsets: MEDLINE

Variability of the QuantiFERON®-TB Gold In-Tube Test Using Automated and Manual Methods.

Authors: Whitworth, William C. Goodwin, Donald J. Racster, Laura et al.

Source: PLoS ONE. Jan2014, Vol. 9 Issue 1, p1-8. 8p.

Tumour necrosis factor-α receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.

Authors: Pierik, M. Vermeire, S. Steen, K. V. et al.

Source: Alimentary Pharmacology & Therapeutics. Aug2004, Vol. 20 Issue 3, p303-310. 8p. 6 Charts, 3 Graphs.

Elevated Spontaneous Interferon-γ Secretion in Human Immunodeficiency Virus-Infected Persons.

Authors: Sparks, Rachel Koelle, David M. Stern, Joshua E. et al.

Source: Open Forum Infectious Diseases. Spring2017, Vol. 4 Issue 2, p1-3. 3p.